$10.68
-0.27-2.47%
Ult. Agg.: Oct 23, 4:00 PM
ADMA Biologics (ADMA) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ADMA Biologics (ADMA) ha pubblicato l'ultima guidance il agosto 5, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $530M - $560M per il periodo.
Rispetto alle previsioni precedenti, ADMA Biologics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
ADMA Biologics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il ADMA Biologics. 15
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.17 | $0.20 | $0.20 | $0.16 |
| Actual | $0.16 | $0.17 | $0.21 | $0.16 |
| Surprise | -5.88% | -15.0% | +7.50% | 0.00% |
| Revenue | ||||
| Estimate | $126.1M | $140.0M | $139.8M | $130.4M |
| Actual | $124.4M | $114.5M | $139.2M | $134.2M |
| Surprise | -1.34% | -18.2% | -0.46% | +2.96% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.20 | $0.24 | $0.17 | $0.20 |
| Revenue | ||||
| Consensus | $138.5M | $157.1M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.16 | $0.17 | -5.88 % |
| Q1 | May 6, 2026 | $0.17 | $0.20 | -15.0 % |
| Q4 | Feb 25, 2026 | $0.22 | $0.20 | 7.50 % |
| Q3 | Nov 5, 2025 | $0.16 | $0.16 | 0.00 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $124.40M | $126.08M | -1.34 % |
| Q1 | May 6, 2026 | $114.49M | $139.97M | -18.2 % |
| Q4 | Feb 25, 2026 | $139.16M | $139.80M | -0.46 % |
| Q3 | Nov 5, 2025 | $134.22M | $130.36M | 2.96 % |